EC-18 can resolve inflammation by allowing complete viral clearance while minimizing tissue damage, and it may be able to quickly neutralize SARS-CoV-2 by preventing cytokine storm or acute respiratory distress syndrome, according to the company.

Now the company is seeking appropriate partners to develop and commercialize EC-18 worldwide as a potential treatment for COVID-19.

New antiviral drug could work against many viruses, including SARS-CoV-2
An antiviral drug called EIDD-2801 that's in preclinical testing has potential to be developed into the silver bullet that medical professionals seek...

Could a MERS vaccine candidate be the answer for COVID-19?
As researchers urgently work to develop vaccines to prevent COVID-19, many strategies have been considered. Now, a parainfluenza virus 5-based vaccine...

Pfizer, BioNTech give details about mRNA COVID-19 vaccine deal
Biopharmaceutical New Technologies (BioNTech) and Pfizer have released additional details regarding their collaboration to advance the mRNA COVID-19 vaccine...

It's time to enlist research labs in the COVID-19 fight
Careful incorporation of research laboratories into the COVID-19 testing effort could increase capacity in the U.S. and globally, writes molecular diagnostics...